Summary

Rev Mal Respir. 2015 Oct;32(8):867-76. doi: 10.1016/j.rmr.2015.02.091. Epub 2015 Jun 12.

[New targets and new drugs in thoracic oncology]. [Article in French]

Abstract:

A number of mechanisms that drive oncogenesis have been deciphered over the last 20 years. The main oncogenic factors in the field of thoracic oncology are mutations of EGFR, KRAS, and EML4-ALK translocation, which are most often reported in adenocarcinomas. However, new molecular targets have been highlighted recently including BRAF mutations, HER2 or PI3K, new translocations such as ROS1 or KIF5B-RET. Molecular abnormalities have also been identified in tumors other than adenocarcinoma (squamous and small cell carcinoma). Therapeutic strategies have been designed to inhibit these signaling pathways including monoclonal antibodies and tyrosine kinase inhibitors. Some of these molecules are now approved as therapies, others are currently undergoing testing in clinical trials. We here present a review of novel targeted agents for lung cancer.

日本語要旨:

PMID:  26076869

前ページへ戻る

PAGE TOP